Memantine: a review of its use in Alzheimer's disease (Q34557011)

3 August 2017

1 reference

title

Memantine: a review of its use in Alzheimer's disease (English)

1 reference

3 August 2017

0 references

2

Gillian M Keating

1 reference

3 August 2017

Dean M Robinson

1

1 reference

3 August 2017

1 January 2006

1 reference

3 August 2017

1 reference

3 August 2017

66

1 reference

3 August 2017

11

1 reference

3 August 2017

1515-1534

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666110-00015

3 August 2017

0 references

cites work

The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study.

1 reference

12 December 2020

NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.

1 reference

12 December 2020

Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors.

1 reference

12 December 2020

1 reference

12 December 2020

The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

1 reference

12 December 2020

The magnitude of dementia occurrence in the world

1 reference

12 December 2020

Drugs targeting Alzheimer's disease: some things old and some things new.

1 reference

12 December 2020

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

12 December 2020

Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden

1 reference

12 December 2020

Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate

1 reference

12 December 2020

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

12 December 2020

The NMDA antagonist memantine impairs classical eyeblink conditioning in humans.

1 reference

12 December 2020

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

12 December 2020

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

12 December 2020

1 reference

12 December 2020

Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.

1 reference

12 December 2020

Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis

1 reference

12 December 2020

Neuroprotective effect of memantine demonstrated in vivo and in vitro.

1 reference

12 December 2020

The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner

1 reference

12 December 2020

Pharmacological modulation of perceptual learning and associated cortical reorganization

1 reference

12 December 2020

Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans

1 reference

12 December 2020

Non-cholinergic strategies for treating and preventing Alzheimer's disease

1 reference

12 December 2020

Pharmacokinetic study of memantine in healthy and renally impaired subjects

1 reference

12 December 2020

Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective

1 reference

12 December 2020

Treating the full spectrum of dementia with memantine

1 reference

12 December 2020

Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions

1 reference

12 December 2020

Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil

1 reference

12 December 2020

Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease.

1 reference

12 December 2020

A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease

1 reference

12 December 2020

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

1 reference

12 December 2020

Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).

1 reference

12 December 2020

Glutamate receptors as a target for Alzheimer's disease--are clinical results supporting the hope?

1 reference

12 December 2020

Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity

1 reference

12 December 2020

Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man.

1 reference

12 December 2020

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

1 reference

12 December 2020

Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

1 reference

12 December 2020

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

1 reference

12 December 2020

Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity

1 reference

12 December 2020

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

1 reference

12 December 2020

Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.

1 reference

12 December 2020

Management of Alzheimer's disease

1 reference

12 December 2020

Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease

1 reference

12 December 2020

1 reference

12 December 2020

Influence of the N-methyl-D-aspartate antagonist memantine on human motor cortex excitability.

1 reference

12 December 2020

Drug development and Alzheimer disease.

1 reference

12 December 2020

Cost of illness of Alzheimer's disease: how useful are current estimates?

1 reference

12 December 2020

Guidelines for managing Alzheimer's disease: part I. Assessment

1 reference

12 December 2020

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

1 reference

12 December 2020

New approaches to clinical trials in vascular dementia: memantine in small vessel disease

1 reference

12 December 2020

Trapping channel block of NMDA-activated responses by amantadine and memantine

1 reference

12 December 2020

The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis

1 reference

12 December 2020

Guidelines for managing Alzheimer's disease: Part II. Treatment.

1 reference

12 December 2020

Memantine in moderate-to-severe Alzheimer's disease

1 reference

12 December 2020

Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease : a markov model in Finland

1 reference

12 December 2020

The epidemic of Alzheimer's disease. How can we manage the costs?

1 reference

12 December 2020

Age-specific incidence of Alzheimer's disease in a community population.

1 reference

12 December 2020

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

1 reference

12 December 2020

No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.

1 reference

12 December 2020

Case management guideline: Alzheimer disease and other dementias

1 reference

12 December 2020

The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain

1 reference

12 December 2020

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

1 reference

12 December 2020

Current drugs and future hopes in the treatment of Alzheimer's disease.

1 reference

12 December 2020

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

1 reference

12 December 2020

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

1 reference

12 December 2020

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

1 reference

12 December 2020

Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage

1 reference

12 December 2020

Vitamin E and donepezil for the treatment of mild cognitive impairment

1 reference

12 December 2020

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

1 reference

12 December 2020

Memantine enhances autonomy in moderate to severe Alzheimer's disease

1 reference

12 December 2020

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

12 December 2020

Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B.

1 reference

12 December 2020

NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine.

1 reference

12 December 2020

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

1 reference

12 December 2020

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

1 reference

12 December 2020

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

1 reference

12 December 2020

Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration

1 reference

12 December 2020

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

12 December 2020

Memantine prevents progressive functional neurodegeneration in rats.

1 reference

12 December 2020

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

1 reference

12 December 2020

10.2165/00003495-200666110-00015

Identifiers

DOI

1 reference

PubMed ID

16906789

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

16906789